Risankizumab Treatment Showed Efficacy for Psoriasis
The UnlIMMited trial demonstrated significant symptom reduction for genital and scalp psoriasis over 52 weeks.
Updated on Oct. 5, 2026 in Sex Life
Live Poll
Do you believe new pharmaceutical treatments effectively improve the daily quality of life for chronic patients?
Results from the UnlIMMited trial indicate that risankizumab effectively treats genital and scalp psoriasis. Patients receiving the treatment experienced high rates of skin clearance and improved quality of life metrics.
Why it matters
Psoriasis in sensitive areas often significantly impacts patient quality of life and physical comfort. This trial provides clinical data on a treatment option that addresses these specific, difficult-to-manage symptoms.
At week 52, 81.5% of patients on continuous risankizumab achieved skin clearance scores of 0 or 1. Additionally, participants reported a reduction in genital itch of approximately 80%.
The players
UnlIMMited trial
This is the clinical research study evaluating the efficacy of risankizumab for specific types of psoriasis.
The details
The UnlIMMited trial utilized sPGA-G and scalp IGA scores to measure skin clearance across 52 weeks of treatment. Over half of the study participants reported a Dermatology Life Quality Index score of 0 or 1 by the end of the trial period.
Timeline
September 30-October 3, 2026: EADV Congress held in Vienna.
Week 16: Intermediate efficacy results measured.
Week 52: Final efficacy results measured.
Culture Shift
The study marks a shift toward addressing specific, sensitive dermatological conditions that were historically underserved in clinical research. This data extends the findings of the UnlIMMited clinical trial to help inform long-term patient care strategies.
Patients dealing with genital or scalp psoriasis may now have improved treatment options that significantly reduce itch and clear skin. Discussing these clinical findings with a dermatologist can help determine if this treatment approach fits your specific health needs.
The takeaway
These findings underscore the importance of targeted therapies for dermatological conditions that impact daily comfort and confidence. Patients should consult with medical professionals to assess how these evolving treatment options might improve their personal health outcomes.
Further reading
For more information on dermatological health and intimacy, visit Sex Life.
More information
Read the full UnlIMMited clinical trial details on the official registry.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you believe new pharmaceutical treatments effectively improve the daily quality of life for chronic patients?
